Success of Immunosuppressive Treatments in Patients with Chronic Graft-versus-Host Disease
Stephanie J. Lee(Fred Hutch Cancer Center), Mary E.D. Flowers(City Of Hope National Medical Center), Tam D. Nguyen(University of North Carolina at Chapel Hill), Lynn Onstad(Fred Hutch Cancer Center), Rachel B. Salit(Johns Hopkins Hospital), Morgani Rodrigues(Hospital Israelita Albert Einstein), Paul J. Martin(European Society for Blood and Marrow Transplantation), Merav Bar(Fred Hutch Cancer Center), Elizabeth F. Krakow(Fred Hutch Cancer Center), Anne M. Hall(Fred Hutch Cancer Center), Barry E. Storer(City Of Hope National Medical Center), Paul A. Carpenter(Fred Hutch Cancer Center)
Cited by 87
Related Papers
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report
|Biology of Blood and Marrow Transplantation|2014|5.4k
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis
|Cancer Cell|2005|3k
American Society of Clinical Oncology Recommendations on Fertility Preservation in Cancer Patients
|Journal of Clinical Oncology|2006|2k
HLA-Haploidentical Bone Marrow Transplantation for Hematologic Malignancies Using Nonmyeloablative Conditioning and High-Dose, Posttransplantation Cyclophosphamide
|Biology of Blood and Marrow Transplantation|2008|1.9k
Methotrexate and Cyclosporine Compared with Cyclosporine Alone for Prophylaxis of Acute Graft versus Host Disease after Marrow Transplantation for Leukemia
|New England Journal of Medicine|1986|1.5k